Marshall Wace’s NewAmsterdam Pharma NAMS Stock Holding History

Marshall Wace’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.48M	Buy	+264,802	New	+$8.63M	0.01%	1054
2025 Q1	–	Sell	-288,446	Closed	-$7.41M	–	2930
2024 Q4	$7.41M	Buy	288,446 +178,322	+162%	+$3.79M	0.01%	905
2024 Q3	$1.83M	Buy	110,124 +88,293	+404%	+$1.53M	﹤0.01%	1405
2024 Q2	$419K	Sell	21,831 -93,549	-81%	-$1.88M	﹤0.01%	2027
2024 Q1	$2.73M	Buy	115,380 +81,439	+240%	+$1.65M	﹤0.01%	1230
2023 Q4	$379K	Buy	33,941 +23,777	+234%	+$218K	﹤0.01%	1811
2023 Q3	$94K	Sell	10,164 -15,197	-60%	-$165K	﹤0.01%	2049
2023 Q2	$302K	Buy	+25,361	New	+$336K	﹤0.01%	2139

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Marshall Wace's NAMS Position: Q1 2026 in Review

Marshall Wace opened a new position in NewAmsterdam Pharma (NAMS) in Q1 2026: 264,802 shares worth $8.48M. The stake represents 0.01% of the portfolio and ranks #1054 among its holdings. This is a return to the name: Marshall Wace previously reported a position in NAMS as recently as Q4 2024.

Marshall Wace first reported a position in NAMS in Q2 2023 and has held it in 8 quarters since. 170 funds tracked by Wall St. Rank hold NAMS as of Q1 2026.

Marshall Wace held 264,802 shares of NewAmsterdam Pharma worth $8.48M as of Q1 2026.
NewAmsterdam Pharma was a new Marshall Wace position in Q1 2026.
NewAmsterdam Pharma made up 0.01% of Marshall Wace's portfolio in Q1 2026, its #1054 holding.
Marshall Wace first reported a position in NewAmsterdam Pharma in Q2 2023 and has held it in 8 quarters since.
170 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.